Newly Launched Replay Has Big Plans For Writing and Delivering ‘Big DNA’
Viral Vector Has 30 Times Capacity Of AAV
Executive Summary
With a hub-and-spoke model, Replay has ambitious plans to solve multiple problems in genetic medicine and to disrupt the current AAV gene therapy model.
You may also be interested in...
Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat
Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.
Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.
Speculation Grows On Potential Big Pharma Buyout Of Mirati
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.